Chimeric Antigen Receptor Natural Killer Cells clinical trials
How each study uses Chimeric Antigen Receptor Natural Killer Cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Chimeric Antigen Receptor Natural Killer Cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
The Second Hospital of Shandong University (1) · YANRU WANG (1) · Hangzhou Cheetah Cell Therapeutics Co., Ltd (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Chimeric Antigen Receptor Natural Killer Cells.
- Dec 2026A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune DiseasesEarly Phase 1 · YANRU WANG
Studies
Open first, then newest update. How each study uses Chimeric Antigen Receptor Natural Killer Cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune DiseasesRecruitingEarly Phase 1YANRU WANGNCT06318533Written as CAR NK cellsHow we know
- Safety and Efficacy of CD19 CAR-T/CAR-NK CellsActive, not recruitingEarly Phase 1The Second Hospital of Shandong UniversityNCT06596057Written as CAR-T/CAR-NK cellsHow we know
- NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNot applicableHangzhou Cheetah Cell Therapeutics Co., LtdNCT05247957Written as CAR-NK cellsHow we know